# Study of Aprepitant (MK-0869) for Chemotherapy-Induced Nausea and Vomiting (CINV) in Adolescent Participants (MK-0869-097)

> **NCT00080444** · PHASE3 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 50 (actual)

## Conditions studied

- Vomiting

## Interventions

- **DRUG:** aprepitant
- **DRUG:** ondansetron
- **DRUG:** dexamethasone
- **DRUG:** placebo to aprepitant
- **DRUG:** placebo to dexamethasone
- **DRUG:** rescue medication

## Key facts

- **NCT ID:** NCT00080444
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-04
- **Primary completion:** 2006-09
- **Final completion:** 2007-03
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2014-08-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00080444

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00080444, "Study of Aprepitant (MK-0869) for Chemotherapy-Induced Nausea and Vomiting (CINV) in Adolescent Participants (MK-0869-097)". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00080444. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*